217 related articles for article (PubMed ID: 36577468)
21. Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.
Lu C; Chen Y; Zhang Y; Zhao X
Diabetes Metab Syndr Obes; 2023; 16():2627-2637. PubMed ID: 37663203
[TBL] [Abstract][Full Text] [Related]
22. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease.
Chen X; Goh GB; Huang J; Wu Y; Wang M; Kumar R; Lin S; Zhu Y
J Clin Transl Hepatol; 2022 Aug; 10(4):589-594. PubMed ID: 36062270
[TBL] [Abstract][Full Text] [Related]
23. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
[TBL] [Abstract][Full Text] [Related]
24. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
27. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
28. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
30. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease.
Yang C; He Q; Chen Z; Qin JJ; Lei F; Liu YM; Liu W; Chen MM; Sun T; Zhu Q; Wu Y; Zhuo M; Cai J; Mao W; Li H
Front Endocrinol (Lausanne); 2022; 13():821689. PubMed ID: 35250880
[TBL] [Abstract][Full Text] [Related]
31. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
32. A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study.
Xie J; Xu L; Huang H; Chen Y; Wang J; Li Y; Yu C; Xu C
Hepatol Int; 2023 Oct; 17(5):1182-1191. PubMed ID: 37322380
[TBL] [Abstract][Full Text] [Related]
33. The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease.
Wu T; Ye J; Shao C; Lin Y; Wang W; Feng S; Zhong B
Clin Transl Gastroenterol; 2022 Jul; 13(7):e00504. PubMed ID: 35608296
[TBL] [Abstract][Full Text] [Related]
34. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
Cheung JTK; Zhang X; Wong GL; Yip TC; Lin H; Li G; Leung HH; Lai JC; Mahadeva S; Nik Mustapha NR; Wang XD; Liu WY; Wong VW; Chan WK; Zheng MH
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1194-1204. PubMed ID: 37724633
[TBL] [Abstract][Full Text] [Related]
35. Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease.
Lee CH; Lui DT; Li RH; Yuen MM; Fong CH; Leung AP; Chu JC; Mak LL; Lam TH; Woo J; Woo YC; Xu A; Tse HF; Tan KC; Cheung BM; Yuen MF; Lam KS
Front Endocrinol (Lausanne); 2022; 13():1056562. PubMed ID: 36686469
[TBL] [Abstract][Full Text] [Related]
36. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
37. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation.
Decoin R; Butruille L; Defrancq T; Robert J; Destrait N; Coisne A; Aghezzaf S; Woitrain E; Gouda Z; Schino S; Klein C; Maboudou P; Brigadeau F; Klug D; Vincentelli A; Dombrowicz D; Staels B; Montaigne D; Ninni S
Front Endocrinol (Lausanne); 2022; 13():957245. PubMed ID: 36120456
[TBL] [Abstract][Full Text] [Related]
38. Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis.
Rodríguez-Antonio I; López-Sánchez GN; Reyes-Gómez VA; Contreras-Flores EH; Farías-García F; Espejel-Deloiza M; Durán-Padilla MA; Chablé-Montero F; Uribe M; Chávez-Tapia NC; Montalvo-Javé EE; Nuño-Lámbarri N
Ann Hepatol; 2022; 27(2):100651. PubMed ID: 34896638
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories.
Ciardullo S; Monti T; Sala I; Grassi G; Mancia G; Perseghin G
Hypertension; 2020 Aug; 76(2):562-568. PubMed ID: 32594797
[TBL] [Abstract][Full Text] [Related]
40. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.
Sohn W; Kwon HJ; Chang Y; Ryu S; Cho YK
Clin Gastroenterol Hepatol; 2022 May; 20(5):e1135-e1148. PubMed ID: 34224877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
